Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?

To: BigKNY3 who wrote (6793)	1/24/1999 9:23:00 PM
From: BigKNY3	Read Replies (1) \| Respond to of 9523

James Cramer Predicts A Rotation Swing This Week BigKNY3 Tech will take a back seat this week to the soft-goods players. It won't happen intentionally; it is just that after a couple of days of bond strength and tech weakness, we are now in day two of the rotation into safety. The assault against safety, however, is also in full swing. Merck (MRK:NYSE) missed out on a promising antidepression drug on Friday, causing someone to puke up six figures worth of the stock well after the closing. (I stuck around to participate on the buy side, alienating everyone at home and missing a fabu Italian dinner.) The trade went on all the way down at 138. If the print, which is slang for where the trade went on, holds, it could be a good sign for the group. But the fact that people bail from Merck so easily now shows how skittish this market has become. We used to save our bailing for tech!! Don't forget the Eli Lilly (LLY:NYSE) trial, the one where Prozac's patent is in doubt. A win here could restore some of the luster to the poorest-acting drug stock around. Monsanto (MTC:NYSE) and Pfizer (PFE:NYSE) will begin training their sales forces for Celebrex, the already celebrated antipain drug (good points about this made in Barron's) and Warner-Lambert (WLA:NYSE) reports and tries to put a good spin on Rezulin.